Table 1. Pathologic complete response rates after neoadjuvant SABR for resectable early-stage NSCLC.

Author	Trial name	Year	Treatment regimen	N surgically-resected*	pCR rate	Time between neoadjuvant therapy and resection	Comment
Palma et al.	MISSILE-NSCLC (NCT02136355)	2019	Neoadjuvant SABR plus surgery	35	60%	10 weeks	2-year OS: 77%
							2-year local control: 100%
							2-year regional control: 53%
							2-year distant control: 76%

*, one pathology specimen was improperly fixated in formalin and thus could not be analyzed. SABR, stereotactic ablative radiotherapy; N, number of patients; NSCLC, non-small cell lung cancer; pCR, pathologic complete response.